Taysha Gene Therapies Inc (NAS:TSHA)

$ 1.93 0.05 (2.66%) Market Cap: 395.54 Mil Enterprise Value: 290.14 Mil PE Ratio: 0 PB Ratio: 4.49 GF Score: 36/100

Q3 2024 Taysha Gene Therapies Inc Earnings Call Transcript
Nov 13, 2024

$2.21 (-7.53%)

Earnings
Q2 2024 Taysha Gene Therapies Inc Earnings Call Transcript
Aug 12, 2024

$2.04 (-2.39%)

Earnings
Q1 2024 Taysha Gene Therapies Inc Earnings Call Transcript
May 14, 2024

$2.57 (+7.08%)

Earnings
Q4 2023 Taysha Gene Therapies Inc Earnings Call Transcript
Mar 19, 2024

$2.25 (+5.63%)

Earnings
Q3 2023 Taysha Gene Therapies Inc Earnings Call Transcript
Nov 14, 2023

$1.33

Earnings
Q2 2023 Taysha Gene Therapies Inc Earnings Call Transcript
Aug 14, 2023

$2.13 (+188.23%)

Earnings
Taysha Gene Therapies Inc R&D Day Transcript
Jun 28, 2023
Q1 2023 Taysha Gene Therapies Inc Earnings Call Transcript
May 11, 2023

$0.709 (-5.47%)

Earnings
Q4 2022 Taysha Gene Therapies Inc Earnings Call Transcript
Mar 28, 2023

$0.652 (-6.19%)

Earnings
Taysha Gene Therapies Inc Corporate Update Call Transcript
Jan 31, 2023
Q3 2022 Taysha Gene Therapies Inc Earnings Call Transcript
Nov 08, 2022

$2.2 (+10.00%)

Earnings
Taysha Gene Therapies Inc to Discuss Astellas Pharma's Strategic InvestmentCall Transcript
Oct 25, 2022
Q2 2022 Taysha Gene Therapies Inc Earnings Call Transcript
Aug 11, 2022

$3.95 (-19.06%)

Earnings
Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Q1 2022 Taysha Gene Therapies Inc Earnings Call Transcript
May 16, 2022

$3.32 (-3.49%)

Earnings
Taysha Gene Therapies Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Taysha Gene Therapies Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Apr 01, 2022
Q4 2021 Taysha Gene Therapies Inc Earnings Call Transcript
Mar 31, 2022

$6.52 (+6.02%)

Earnings
Taysha Gene Therapies Inc To Discuss TSHA-120 GAN Program Update Call Transcript
Jan 31, 2022
Taysha Gene Therapies Inc To Discuss TSHA-101 In GM2 Gangliosidosis Program Update Call Transcript
Jan 27, 2022
Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Q3 2021 Taysha Gene Therapies Inc Earnings Call Transcript
Nov 10, 2021

$15.74 (+5.14%)

Earnings
Taysha Gene Therapies Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Oct 28, 2021
Taysha Gene Therapies Inc Angelman Syndrome Investor Day Transcript
Oct 26, 2021
Taysha Gene Therapies Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
Taysha Gene Therapies Inc To Discuss CLN7 Program Acquisition Call Transcript
Oct 05, 2021
Taysha Gene Therapies Inc To Host Virtual Key Opinion Leader (KOL) Webinar On TSHA-102 For Treatment Of Rett Syndrome Call Transcript
Sep 22, 2021
Taysha Gene Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Taysha Gene Therapies Inc To Host CLN1 KOL Webinar Transcript
Aug 30, 2021
Q2 2021 Taysha Gene Therapies Inc Earnings Call Transcript
Aug 16, 2021

$15.82 (-8.98%)

Earnings
Taysha Gene Therapies Inc To Host Manufacturing Investor Day Transcript
Jul 27, 2021
Taysha Gene Therapies Inc R&D Day 2 Transcript
Jun 29, 2021
Taysha Gene Therapies Inc R&D Day 1 Transcript
Jun 28, 2021
Taysha Gene Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Taysha Gene Therapies Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021
Q1 2021 Taysha Gene Therapies Inc Earnings Call Transcript
May 11, 2021

$21 (+2.34%)

Earnings
Taysha Gene Therapies Inc GAN Program Acquisition Call Transcript
Apr 12, 2021
Full Year 2020 Taysha Gene Therapies Inc Earnings Call Transcript
Mar 03, 2021

$25.21

Earnings

Taysha Gene Therapies Inc Angelman Syndrome Investor Day Transcript

Oct 26, 2021 / 02:00PM GMT

Release Date Price: $16.15 (+1.25%)

Transcript 8-K

Kimberly Lee

Taysha Gene Therapies, Inc. - SVP of Corporate Communications & IR

Good morning, and welcome to Taysha Gene Therapies Angelman Syndrome Investor Day. (Operator Instructions) Today, we will provide an overview of Angelman syndrome, hear from a patient advocate and discuss the TSHA-106 program and clinical development strategy.

Joining the call today is R. Session, II, Taysha's President, Founder and CEO; Dr. Ben Philpot, our key opinion leader, guest speaker from the University of North Carolina at Chapel Hill; Dr. Kimberly Goodspeed, Assistant Professor in the Department of Pediatrics and Neurology at UT Southwestern; Dr. Allyson Berent, Chief Scientific Officer of the Foundation for Angelman Therapeutics or FAST; and Dr. Ryan Butler, Assistant Professor in the Department of Psychiatry and Pediatrics at UT Southwestern; and Dr. Suyash Prasad, Taysha's Chief Medical Officer and Head of R&D.

Next slide, please. Before we begin, please note that this presentation will include forward-looking statements within the meaning of the safe harbor provisions of the Private

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.